PEN logo

Penumbra, Inc. Stock Price

NYSE:PEN Community·US$10.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

PEN Share Price Performance

US$255.61
64.80 (33.96%)
15.7% undervalued intrinsic discount
US$303.33
Fair Value
US$255.61
64.80 (33.96%)
15.7% undervalued intrinsic discount
US$303.33
Fair Value
Price US$255.61
AnalystConsensusTarget US$303.33

PEN Community Narratives

AnalystConsensusTarget·Updated
Fair Value US$303.33 15.7% undervalued intrinsic discount

STORM-PE Trial And New Therapies Will Expand Global Reach

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Recent PEN News & Updates

Results: Penumbra, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 01
Results: Penumbra, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Jun 26

The Return Trends At Penumbra (NYSE:PEN) Look Promising

Jun 23
The Return Trends At Penumbra (NYSE:PEN) Look Promising

Penumbra, Inc. Key Details

US$1.3b

Revenue

US$429.3m

Cost of Revenue

US$850.9m

Gross Profit

US$703.2m

Other Expenses

US$147.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
3.79
Gross Margin
66.47%
Net Profit Margin
11.54%
Debt/Equity Ratio
0%

Penumbra, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
2 Rewards

About PEN

Founded
2004
Employees
4500
CEO
Adam Elsesser
WebsiteView website
www.penumbrainc.com

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.9%
  • 3 Months: 8.7%
  • 1 Year: 18.4%
  • Year to Date: 14.8%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 6.4% in that time. As for the longer term, the market has risen 18% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›